WO2009019693A3 - Analgesic effect of jasmonate derivatives - Google Patents
Analgesic effect of jasmonate derivatives Download PDFInfo
- Publication number
- WO2009019693A3 WO2009019693A3 PCT/IL2008/001083 IL2008001083W WO2009019693A3 WO 2009019693 A3 WO2009019693 A3 WO 2009019693A3 IL 2008001083 W IL2008001083 W IL 2008001083W WO 2009019693 A3 WO2009019693 A3 WO 2009019693A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analgesic effect
- jasmonate derivatives
- jasmonate
- derivatives
- jasmonate derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
Abstract
The present invention relates to the treatment, alleviation or prevention of pain by administering a composition comprising a jasmonate derivative which binds to opioid receptors. The jasmonate derivative can be administered alone or in combination with one or more additional therapeutic agents.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95432607P | 2007-08-07 | 2007-08-07 | |
US60/954,326 | 2007-08-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009019693A2 WO2009019693A2 (en) | 2009-02-12 |
WO2009019693A3 true WO2009019693A3 (en) | 2010-03-04 |
Family
ID=40341858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2008/001083 WO2009019693A2 (en) | 2007-08-07 | 2008-08-07 | Analgesic effect of jasmonate derivatives |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009019693A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012079058A2 (en) | 2010-12-10 | 2012-06-14 | Broady Health Sciences, Llc | Use of jasmonate to treat bladder dysfunction |
US20140220132A1 (en) * | 2011-02-25 | 2014-08-07 | José E. Fehr Pereira Lopes | Pharmaceutical Formulation Comprising Compounds of the Jasmonate Family |
WO2013040556A1 (en) | 2011-09-16 | 2013-03-21 | Nanocare Technologies, Inc. | Compositions of jasmonate compounds and methods of use |
BR112017014229A2 (en) | 2014-12-31 | 2018-03-06 | Nanocare Technologies, Inc. | conjugate, composition, and method for treating a disorder. |
KR102543754B1 (en) * | 2021-09-15 | 2023-06-14 | 김민경 | Injection composition for lipolysis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050260758A1 (en) * | 2004-02-27 | 2005-11-24 | Lada Rasochova | High efficiency peptide production in plant cells |
US20060105915A1 (en) * | 1999-06-30 | 2006-05-18 | Marker Gene Technologies, Inc. | Compositions and methods for targeted enzymatic release of cell regulatory compounds |
US20060167102A1 (en) * | 2002-02-04 | 2006-07-27 | L'oreal S.A. | Compositions comprising cyclopentane derivatives and their use |
-
2008
- 2008-08-07 WO PCT/IL2008/001083 patent/WO2009019693A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060105915A1 (en) * | 1999-06-30 | 2006-05-18 | Marker Gene Technologies, Inc. | Compositions and methods for targeted enzymatic release of cell regulatory compounds |
US20060167102A1 (en) * | 2002-02-04 | 2006-07-27 | L'oreal S.A. | Compositions comprising cyclopentane derivatives and their use |
US20050260758A1 (en) * | 2004-02-27 | 2005-11-24 | Lada Rasochova | High efficiency peptide production in plant cells |
Also Published As
Publication number | Publication date |
---|---|
WO2009019693A2 (en) | 2009-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
MX363178B (en) | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders. | |
MX366175B (en) | Concentrated therapeutic phospholipid compositions. | |
WO2005097125A3 (en) | Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease | |
WO2007149797A3 (en) | Use of organic compounds | |
WO2009153665A3 (en) | Inhibitors of the shiga toxins trafficking through the retrograde pathway | |
WO2008157537A3 (en) | Compositions and methods of use for treating or preventing lipid related disorders | |
MX350154B (en) | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1 '-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain. | |
MX2014002171A (en) | Combination treatments for hepatitis c. | |
MX2011008450A (en) | Agonists and antagonists of the s1p5 receptor, and methods of uses thereof. | |
BRPI0713306A8 (en) | PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE AND LOSARTAN | |
HK1176318A1 (en) | Injection device | |
WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
UA93709C2 (en) | 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions | |
WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
WO2009068659A3 (en) | Novel disease treatment by predicting drug association | |
WO2011014825A3 (en) | Antiangiogenic small molecules and methods of use | |
WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
WO2009019693A3 (en) | Analgesic effect of jasmonate derivatives | |
WO2012012305A3 (en) | Combination therapy using a ruthenium complex | |
TNSN08506A1 (en) | Substituted carboxamides | |
WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
WO2011055383A3 (en) | Intranasal delivery to improve the performance of children suffering from dyslexia | |
MX2010013484A (en) | Pharmaceutical formulation of ketorolac for intranasal administration. | |
JO2820B1 (en) | Combination of a Bisthiazolium Salt or a Precursor Thereof and Artemisinin or a Derivative Thereof for the Treatment of Severe Malaria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08789759 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08789759 Country of ref document: EP Kind code of ref document: A2 |